Patients diagnosed with cancer can now receive electrochemotherapy, significantly reducing the number of treatments needed for
local tumor control.
Many of the neoplastic diseases we encounter in veterinary practice require a multi-modality approach for successful outcome or even
local tumor control.
Not exact matches
To determine
local immune
control, where the invasive tissue interfaces with normal cells, post-birth placentas and stage - four melanoma
tumors were examined.
Investigating conventional MHC - restricted T cell responses specific for
tumor - associated peptide antigens, and
local immune contextures, in mediating cancer
control in patients following neoadjuvant (per - surgery) therapy.
Intensive
local therapy was followed by up to a year of less intense systemic treatment with cis - retinoic acid (a derivative of vitamin A) and interferon in an effort to
control any microscopic
tumors that had spread to distant sites from the initial cancer.
Multi-center, placebo -
controlled, double - blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either
local or distant) mast cell
tumor following surgical excision.
A top priority for oral melanomas is to gain
local control of the
tumor.
With this option, the
local control rate for melanomas is approximately 80 percent, with most dogs dying of
tumor spread within four to six months.
But combined with RT, it may have also improve
local control of the heart
tumor.